Werewolf Therapeutics Stock Market Outlook
| HOWL Stock | USD 0.67 0.05 6.94% |
About 55% of Werewolf Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Werewolf Therapeutics suggests that many traders are impartial. Werewolf Therapeutics' investing sentiment shows overall attitude of investors towards Werewolf Therapeutics.
Comfort Level 45
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Werewolf Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Werewolf Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Werewolf Therapeutics is 'Strong Sell'. The recommendation algorithm takes into account all of Werewolf Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Execute Werewolf Therapeutics Advice
The Werewolf recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Werewolf Therapeutics. Macroaxis does not own or have any residual interests in Werewolf Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Werewolf Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weakest | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Risky | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
For the selected time horizon Werewolf Therapeutics has a Mean Deviation of 4.74, Standard Deviation of 7.28 and Variance of 53.06We provide recommendation to complement the prevalent expert consensus on Werewolf Therapeutics. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Werewolf Therapeutics is not overpriced, please check out all Werewolf Therapeutics fundamentals, including its ebitda and the relationship between the debt to equity and market capitalization . As Werewolf Therapeutics appears to be a penny stock we also urge to confirm its price to book numbers.
Werewolf Therapeutics Trading Alerts and Improvement Suggestions
| Werewolf Therapeutics generated a negative expected return over the last 90 days | |
| Werewolf Therapeutics has high historical volatility and very poor performance | |
| Werewolf Therapeutics has some characteristics of a very speculative penny stock | |
| Werewolf Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.89 M. Net Loss for the year was (70.52 M) with loss before overhead, payroll, taxes, and interest of (50.48 M). | |
| Werewolf Therapeutics currently holds about 145.71 M in cash with (56.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thelincolnianonline.com: Insider Selling Werewolf Therapeutics Director Sells 20,942.28 in Stock |
Werewolf Therapeutics Returns Distribution Density
The distribution of Werewolf Therapeutics' historical returns is an attempt to chart the uncertainty of Werewolf Therapeutics' future price movements. The chart of the probability distribution of Werewolf Therapeutics daily returns describes the distribution of returns around its average expected value. We use Werewolf Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Werewolf Therapeutics returns is essential to provide solid investment analysis for Werewolf Therapeutics.
| Mean Return | -0.58 | Value At Risk | -8 | Potential Upside | 8.70 | Standard Deviation | 7.28 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Werewolf Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Werewolf Stock Institutional Investors
| Shares | Geode Capital Management, Llc | 2025-06-30 | 328 K | Renaissance Technologies Corp | 2025-06-30 | 316.3 K | Alyeska Investment Group, L.p. | 2025-06-30 | 235.7 K | Goldman Sachs Group Inc | 2025-06-30 | 227.4 K | State Street Corp | 2025-06-30 | 119.2 K | Marshall Wace Asset Management Ltd | 2025-06-30 | 103.8 K | Bridgeway Capital Management, Llc | 2025-06-30 | 102 K | Aqr Capital Management Llc | 2025-06-30 | 92.2 K | Y-intercept (hong Kong) Ltd | 2025-06-30 | 84.4 K | Ra Capital Management, Llc | 2025-06-30 | 6.7 M | Mpm Asset Management, Llc | 2025-06-30 | 4.3 M |
Werewolf Therapeutics Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Investments | (498K) | (3.6M) | (1.1M) | (254K) | (228.6K) | (240.0K) | |
| Change In Cash | 66.1M | (28.3M) | 25.0M | (43.4M) | (39.0M) | (37.1M) | |
| Free Cash Flow | (43.4M) | (44.2M) | (33.4M) | (56.4M) | (50.8M) | (53.3M) | |
| Depreciation | 216K | 1.1M | 1.8M | 1.8M | 2.1M | 2.2M | |
| Other Non Cash Items | 519K | 2.2M | 878K | 1.2M | 1.3M | 1.4M | |
| Capital Expenditures | 498K | 3.6M | 769K | 254K | 292.1K | 277.5K | |
| Net Income | (50.0M) | (53.8M) | (37.4M) | (70.5M) | (63.5M) | (60.3M) | |
| End Period Cash Flow | 158.8M | 130.5M | 155.6M | 112.2M | 129.0M | 122.5M |
Werewolf Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Werewolf Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Werewolf Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Werewolf stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.74 | |
β | Beta against Dow Jones | 1.62 | |
σ | Overall volatility | 7.32 | |
Ir | Information ratio | -0.09 |
Werewolf Therapeutics Volatility Alert
Werewolf Therapeutics is displaying above-average volatility over the selected time horizon. Werewolf Therapeutics is a potential penny stock. Although Werewolf Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Werewolf Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Werewolf instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Werewolf Therapeutics Fundamentals Vs Peers
Comparing Werewolf Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Werewolf Therapeutics' direct or indirect competition across all of the common fundamentals between Werewolf Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Werewolf Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Werewolf Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Werewolf Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Werewolf Therapeutics to competition |
| Fundamentals | Werewolf Therapeutics | Peer Average |
| Return On Equity | -1.22 | -0.31 |
| Return On Asset | -0.41 | -0.14 |
| Current Valuation | 6.26 M | 16.62 B |
| Shares Outstanding | 48.54 M | 571.82 M |
| Shares Owned By Insiders | 5.61 % | 10.09 % |
| Shares Owned By Institutions | 41.90 % | 39.21 % |
| Number Of Shares Shorted | 2.42 M | 4.71 M |
| Price To Earning | 0.84 X | 28.72 X |
| Price To Book | 1.11 X | 9.51 X |
| Price To Sales | 52.22 X | 11.42 X |
| Revenue | 1.89 M | 9.43 B |
| Gross Profit | (50.48 M) | 27.38 B |
| EBITDA | (64.05 M) | 3.9 B |
| Net Income | (70.52 M) | 570.98 M |
| Cash And Equivalents | 145.71 M | 2.7 B |
| Cash Per Share | 4.93 X | 5.01 X |
| Total Debt | 37.09 M | 5.32 B |
| Debt To Equity | 0.12 % | 48.70 % |
| Current Ratio | 5.08 X | 2.16 X |
| Book Value Per Share | 0.63 X | 1.93 K |
| Cash Flow From Operations | (56.19 M) | 971.22 M |
| Short Ratio | 4.75 X | 4.00 X |
| Earnings Per Share | (1.62) X | 3.12 X |
| Price To Earnings To Growth | (0.06) X | 4.89 X |
| Target Price | 5.2 | |
| Number Of Employees | 39 | 18.84 K |
| Beta | 0.78 | -0.15 |
| Market Capitalization | 34.84 M | 19.03 B |
| Total Asset | 126.93 M | 29.47 B |
| Retained Earnings | (414.59 M) | 9.33 B |
| Working Capital | 97.89 M | 1.48 B |
| Net Asset | 126.93 M |
Note: Disposition of 37413 shares by Evnin Luke of Werewolf Therapeutics at 0.55 subject to Rule 16b-3 [view details]
Werewolf Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Werewolf . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 37416.65 | |||
| Daily Balance Of Power | (0.56) | |||
| Rate Of Daily Change | 0.93 | |||
| Day Median Price | 0.7 | |||
| Day Typical Price | 0.69 | |||
| Price Action Indicator | (0.05) | |||
| Period Momentum Indicator | (0.05) |
About Werewolf Therapeutics Buy or Sell Advice
When is the right time to buy or sell Werewolf Therapeutics? Buying financial instruments such as Werewolf Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Werewolf Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Absolute Returns ETFs Thematic Idea Now
Absolute Returns ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Absolute Returns ETFs theme has 54 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Absolute Returns ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Werewolf Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. Market participants price Werewolf higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Werewolf Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Werewolf Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Werewolf Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Werewolf Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Werewolf Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.